No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CSTL240517P25000
- 1.15
- 0.000.00%
15min DelayTrading May 13 12:28 ET
0.00High0.00Low
0.00Open1.15Pre Close0 Volume2 Open Interest25.00Strike Price0.00Turnover161.46%IV-3.83%PremiumMay 17, 2024Expiry Date0.20Intrinsic Value100Multiplier1DDays to Expiry0.95Time Value100Contract SizeAmericanOptions Type-0.5166Delta0.1558Gamma21.57Leverage Ratio-0.4293Theta-0.0005Rho-11.14Eff Leverage0.0063Vega
Intraday
- 5D
- 1D
News
Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference
Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the
Castle Biosciences Expands Evidence Supporting The Performance Of Its TissueCypher Barrett's Esophagus Test In Predicting Future Development Of Esophageal Cancer
Castle Biosciences Expands Evidence Supporting The Performance Of Its TissueCypher Barrett's Esophagus Test In Predicting Future Development Of Esophageal Cancer
Castle Biosciences Expands Evidence Supporting the Performance of Its TissueCypher Barrett's Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share three abstracts supporting the ability of its TissueCypher test to predict risk of progression to esophageal cancer in patients with Barrett's esophagus (BE) at the Digestive Disease Week (DDW) 2024 Annual Meeting, being held May 18-21, 2024, in Washington, D.C.
Castle Biosciences' IDgenetix Test Receives 2024 MedTech Breakthrough Award for "Best Overall Mental Health Solution"
This marks the fourth consecutive year that Castle has earned a MedTech Breakthrough Award for its innovative testing solutions Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative
Castle Biosciences Announced Data From Study Further For Performance Of Its DecisionDx-UM
Castle Biosciences Announced Data From Study Further For Performance Of Its DecisionDx-UM
Castle Biosciences(CSTL.US) Director Sells US$574.68K in Common Stock
$Castle Biosciences(CSTL.US)$ Director BRADBURY DANIEL sold 23,323 shares of common stock on May 6, 2024 at an average price of $24.64 for a total value of $574.68K.Source: Announcement What is statem